<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664725</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3680-I-DDI-02</org_study_id>
    <nct_id>NCT04664725</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion</brief_title>
  <official_title>A Single-center, Open-label, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Repaglinide (CYP2C8 Substrates) and Bupropion (CYP2B6 Substrates) in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics&#xD;
      of Repaglinide and Bupropion&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration(Cmax)</measure>
    <time_frame>Day1 and Day21</time_frame>
    <description>Summary of Pharmacokinetic parameters Maximum Plasma concentration (Cmax) for Repaglinide and Bupropion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve(AUC0-t)</measure>
    <time_frame>Day1 and Day21</time_frame>
    <description>Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve form 0 to any time before the last quantifiable concentration(AUC0-t)for Repaglinide and Bupropion</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Prostate Cancer Patients</condition>
  <arm_group>
    <arm_group_label>SHR3680+ Repaglinide, Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Repaglinide, Bupropion and SHR3680&#xD;
Repaglinide and Bupropion QD on Day 1 and Day 21, SHR3680 240 mg once daily (QD) from Study Day 6 - 26</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide, Bupropion and SHR3680</intervention_name>
    <description>Single dose of oral administration of Repaglinide and Bupropion, Multiple dose of oral of SHR3680</description>
    <arm_group_label>SHR3680+ Repaglinide, Bupropion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. 18 ≤ age ≤75, male;&#xD;
&#xD;
          -  ECOG score of physical condition is 0 ~ 1;&#xD;
&#xD;
          -  The expected survival time is at least 3 months;&#xD;
&#xD;
          -  Prostatic adenocarcinoma confirmed by histological or cytological examination, with no&#xD;
             indication of neuroendocrine or small-cell characteristics;&#xD;
&#xD;
          -  Fasting blood glucose level is: 3.9～6.1mmol/L；&#xD;
&#xD;
          -  The functional level of organs must meet the following requirements (no blood&#xD;
             transfusion or hematopoietic growth factor treatment was received within 2 weeks&#xD;
             before routine blood screening) :&#xD;
&#xD;
               -  ANC ≧ 1.5 x 109 / L;&#xD;
&#xD;
               -  PLT ≧ 80 x 109 / L;&#xD;
&#xD;
               -  Hb ≧ 90 g/L;&#xD;
&#xD;
               -  TBIL ≦1.5 x ULN;&#xD;
&#xD;
               -  ALT and AST≦2.5×ULN;&#xD;
&#xD;
               -  BUN and Cr ≦1.5 x ULN;&#xD;
&#xD;
               -  GFR ≧ 60 ml/min / 1.73 m2.&#xD;
&#xD;
          -  According to the researcher's judgment, it can comply with the experimental scheme;&#xD;
&#xD;
          -  Volunteer to participate in this clinical trial, understand the study procedures and&#xD;
             have signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous anti-tumor therapy (including radiotherapy, chemotherapy, surgery,&#xD;
             molecular targeted therapy, immunotherapy, etc.), except ADT therapy, shall be&#xD;
             completed until the washout period of the first drug administration in this study is&#xD;
             &lt;4 weeks;&#xD;
&#xD;
          -  Plan to receive any other anti-tumor therapy during the study;&#xD;
&#xD;
          -  As subjects, to participate in other drug clinical trials, the last trial drug&#xD;
             administration is less than 4 weeks from the first administration of the drug in this&#xD;
             study;&#xD;
&#xD;
          -  The presence of intracerebral tumor lesions according to imaging diagnosis;&#xD;
&#xD;
          -  Have a history of epilepsy, or have diseases that can induce epileptic seizures within&#xD;
             12 months before the first administration of the drug in this study (including a&#xD;
             history of transient ischemic attack, cerebral stroke (except cerebral ischemia&#xD;
             lesions found by simple imaging examination), and need to be hospitalized with&#xD;
             cerebral trauma and consciousness disorder);&#xD;
&#xD;
          -  Active heart disease, including severe/unstable angina, myocardial infarction,&#xD;
             symptomatic congestive heart failure, and drug-requiring ventricular arrhythmias,&#xD;
             within 6 months prior to the first administration of the drug in this study;&#xD;
&#xD;
          -  Inability to swallow, chronic diarrhea and ileus, history of gastrointestinal surgery,&#xD;
             or other factors affecting drug use and absorption as determined by the investigator;&#xD;
&#xD;
          -  Patients with active HBV or HCV infection (HBV copy count ≥ 104 copies /mL, HCV copy&#xD;
             count ≥ 103 copies /mL) and active syphilis;&#xD;
&#xD;
          -  A history of immunodeficiency (including HIV positive, other acquired or congenital&#xD;
             immunodeficiency diseases) or a history of organ transplantation;&#xD;
&#xD;
          -  Patients who were unwilling to use effective contraceptive methods during the whole&#xD;
             study treatment period and within 3 months after the last administration;&#xD;
&#xD;
          -  Allergic constitution, including a history of severe drug allergy or drug allergy;&#xD;
&#xD;
          -  Screening for excessive smoking in the first 6 months (≥5 cigarettes/day) or smoking&#xD;
             within 48 hours before the first dose, or not interrupting smokers during the main&#xD;
             study trial, and screening for drug use in the first 3 months with a history of drug&#xD;
             abuse or positive drug abuse screening;&#xD;
&#xD;
          -  has a history of alcoholism or within 6 months prior to screening often drinkers,&#xD;
             namely the essence of drinking more than 14 units of alcohol a week (1 = 360 mL of&#xD;
             alcohol content of 5% beer or 45 mL of 40% alcohol liquor or 150 mL wine alcohol&#xD;
             content of 12%) or within 48 h before taking the medicine for the first time drinking,&#xD;
             or D - 1 in the alcohol breath test positive, or the body can't stop alcohol intake&#xD;
             during the study period;&#xD;
&#xD;
          -  Use of any vitamin product, health product or herb 14 days prior to the first&#xD;
             administration;&#xD;
&#xD;
          -  Ingestion of grapefruit or fruit juice products such as grapefruit, foods or beverages&#xD;
             containing caffeine, xanthine or alcohol within 48 hours before taking the study&#xD;
             drug;Strenuous exercise, or other factors affecting drug absorption, distribution,&#xD;
             metabolism, and excretion;&#xD;
&#xD;
          -  Within 2 weeks before the first drug uptake, uptake CYP2C8 and CYP2B6 inhibitors were&#xD;
             used, or drugs affecting gastric acid secretion.;&#xD;
&#xD;
          -  abnormal coagulation function at screening stage (INR &gt;1.5 or prothrombin time (PT) &gt;&#xD;
             ULN+4 seconds or APTT&gt; 1.5uln), bleeding tendency or thrombolytic therapy;&#xD;
&#xD;
          -  Repaglinide contraindications (insulin-dependent -IDDM, C-peptide-negative diabetic&#xD;
             patients, diabetic ketoacidosis with or without coma);&#xD;
&#xD;
          -  Contraindications to bulimia or anorexia (epileptic history, bulimia or anorexia,&#xD;
             abstinence from alcohol or sedatives suddenly);&#xD;
&#xD;
          -  Those with a history of fainting needle or blood, have difficulty in blood collection&#xD;
             or cannot tolerate vein puncture for blood collection;&#xD;
&#xD;
          -  Concomitant diseases (such as poorly controlled hypertension, severe diabetes, thyroid&#xD;
             disease, psychosis, etc.) or any other conditions that, in the investigator's&#xD;
             judgment, would seriously endanger the patient's safety or affect the patient's&#xD;
             completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiqing Han, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuya Wang, Ph.D</last_name>
    <phone>13918749176</phone>
    <email>wangyuya@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>shijuan kuang, Master</last_name>
    <phone>13601827797</phone>
    <email>kuangshijuan@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiqing Han, Ph.D</last_name>
      <phone>+86-18684699859</phone>
      <email>md70210@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

